Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Dermatology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/182157 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553284070539264 |
|---|---|
| author | Gérald E. Piérard François Aubin Philippe Humbert |
| author_facet | Gérald E. Piérard François Aubin Philippe Humbert |
| author_sort | Gérald E. Piérard |
| collection | DOAJ |
| description | Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its anti-MM activity. Under treatment, the overall survival of patients with MM metastases is moderately but significantly increased. The immuno-related adverse effects may be severe and life threatening. |
| format | Article |
| id | doaj-art-ad3e9616651d4a409ff4e4466b665e71 |
| institution | Kabale University |
| issn | 1687-6105 1687-6113 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Dermatology Research and Practice |
| spelling | doaj-art-ad3e9616651d4a409ff4e4466b665e712025-02-03T05:54:31ZengWileyDermatology Research and Practice1687-61051687-61132012-01-01201210.1155/2012/182157182157Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?Gérald E. Piérard0François Aubin1Philippe Humbert2Department of Dermatopathology, University Hospital of Liège, 4000 Lièg, BelgiumDepartment of Dermatology, University Hospital of Besançon, 25000 Besançon, FranceDepartment of Dermatology, University Hospital of Besançon, 25000 Besançon, FranceMalignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its anti-MM activity. Under treatment, the overall survival of patients with MM metastases is moderately but significantly increased. The immuno-related adverse effects may be severe and life threatening.http://dx.doi.org/10.1155/2012/182157 |
| spellingShingle | Gérald E. Piérard François Aubin Philippe Humbert Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma? Dermatology Research and Practice |
| title | Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma? |
| title_full | Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma? |
| title_fullStr | Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma? |
| title_full_unstemmed | Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma? |
| title_short | Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma? |
| title_sort | ipilimumab a promising immunotherapy with increased overall survival in metastatic melanoma |
| url | http://dx.doi.org/10.1155/2012/182157 |
| work_keys_str_mv | AT geraldepierard ipilimumabapromisingimmunotherapywithincreasedoverallsurvivalinmetastaticmelanoma AT francoisaubin ipilimumabapromisingimmunotherapywithincreasedoverallsurvivalinmetastaticmelanoma AT philippehumbert ipilimumabapromisingimmunotherapywithincreasedoverallsurvivalinmetastaticmelanoma |